← Leaderboards
David Schenkein
Tufts Medical Center
$42,739
Attributed
$42,739
Total exposure
2
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$42,739 · 2
By mechanism
M01$42,739 · 2
Top collaborators
No co-investigators on record.
Most similar at Tufts Medical Center
Same institution · by research overlap
- Wei Li$15,618,115
- Iris Z Jaffe$20,757,672
- Francine M Foss$122,062
- John K Erban$2,404,976
- Lauren Alysse Biwer$744,024
Others in their field
Top investigators on “Drug Screening /Evaluation”
- Fred M Gordin · Social And Scientific Systems, Inc.$68,001,399
- John C S Breitner · Johns Hopkins University$33,065,187
- Philip J Disaia · University Of California Irvine$21,551,991
- George R Painter · Chimerix, Inc.$19,230,662
- Gregory H Reaman · National Childhood Cancer Foundation$17,052,970
- Stephen J Durako · Westat, Inc.$15,048,684
Research focus
Drug Screening /EvaluationAntineoplastic AntibioticsHuman SubjectHuman Therapy EvaluationMonoclonal AntibodyNeoplasm /Cancer ChemotherapyClinical ResearchAcute Myelogenous LeukemiaNeoplasm /Cancer ImmunotherapyNeoplasm /Cancer Relapse /RecurrenceAgingAntiantibodyAntineoplasticsCd AntigensClinical Trial Phase ICytotoxicityHuman Old Age (65+)
Grant awards (6)
S&E OF CMA 676 IN TREATMENT OF ELDERLY--ACUTE MYELOID LEUKEMIA IN FIRST RELAPSE$0
M01 · FY2002 · RR
Efficacy &safety of CMA676 in acute myeloid leukemia in final relapse$0
M01 · FY2002 · RR
S&E OF CMA 676 IN TREATMENT OF ELDERLY--ACUTE MYELOID LEUKEMIA IN FIRST RELAPSE$0
M01 · FY2001 · RR
Efficacy &safety of CMA676 in acute myeloid leukemia in final relapse$0
M01 · FY2001 · RR
S&E OF CMA 676 IN TREATMENT OF ELDERLY--ACUTE MYELOID LEUKEMIA IN FIRST RELAPSE$42,739
M01 · FY2000 · RR
Efficacy &safety of CMA676 in acute myeloid leukemia in final relapse$0
M01 · FY2000 · RR